RVL Pharmaceuticals Plc

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch RVLPQ and buy or sell other stocks, ETFs, and their options commission-free!

About RVLPQ

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, Lorzone, and M-72. 

CEO
Brian A. Markison, CPA
CEOBrian A. Markison, CPA
Employees
125
Employees125
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1986
Founded1986
Employees
125
Employees125

RVLPQ Key Statistics

Market cap
11.14K
Market cap11.14K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.64K
Average volume1.64K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.0001
52 Week high$0.0001
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

The current RVL Pharmaceuticals Plc(RVLPQ) stock price is $0.00, with a market capitalization of 11.14K.

RVL Pharmaceuticals Plc(RVLPQ) stock opened on 2026-04-03 at —. The price climbed to — and dipped to —.

The RVL Pharmaceuticals Plc(RVLPQ)'s current trading volume is 0, compared to an average daily volume of 1.64K.

During the past year, RVL Pharmaceuticals Plc(RVLPQ) stock moved between $0.00 at its lowest and $0.00 at its peak.

During the past year, RVL Pharmaceuticals Plc(RVLPQ) stock moved between $0.00 at its lowest and $0.00 at its peak.

People also own

Based on the portfolios of people who own RVLPQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.